You are here: Industry Insights > Therapix Biosciences

News List

Therapix Biosciences announces Canadian Product License Issuance for CannAmide biospectrumasia
August 01, 2019
This license is issued by Health Canada under the authority of the Natural Health Products Regulations
Therapix Biosciences Announces Interim Results of Phase IIa Study for Obstructive Sleep Apnea americanpharmaceuticalreview
June 20, 2019
Therapix Biosciences announced interim results from its Phase IIa clinical study at Assuta Medical Center in Israel, suggesting that THX-110, a combination of dronabinol (∆-9-tetrahydracannabinol) and CannAmide™ (palmitoylethanolamide, or PEA) ...
Therapix Biosciences Terminates FSD Acquisition Letter of Intent americanpharmaceuticalreview
December 24, 2018
Therapix Biosciences, a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments.....
Therapix Biosciences announces Topline Results for TSP biospectrumasia
April 11, 2018
The study was a single-arm, open-label trial, in which each subject both received one daily treatment of the drug via oral administration and was followed-up for a period of 12 weeks
Therapix Biosciences Announces Topline Results of Phase IIa Study at Yale University for Tourette Syndrome Program biospace
April 10, 2018
TEL AVIV, Israel, April 9, 2018 Therapix Ltd. (NASDAQ: TRPX) ("Therapix" or "the Company"), announced today topline results from its investigator-initiated Phase IIa study at Yale University